ALNYAlnylam Pharmaceuticals, Inc.
$232.57-49% 1Y
$232.57
$216.4652 weeks$491.22
The financials
Alnylam Pharmaceuticals, Inc. by the numbers
Alnylam Pharmaceuticals, Inc. (ALNY) reported revenue of $2.46B in H1 2026 (quarter ended Jun 30, 2026), up 314% from the same quarter a year earlier. That came with a gross margin of 79% and net income of $370M (15% of revenue). For the full year FY2025, revenue was $3.71B (+65% year on year) and net income $314M. Its largest product in H1 2026 was Amvuttra at $809M, 67% of the disclosed total, well ahead of Rare at 12%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
| Income statement | H1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $2.46B | $594M | +314% |
| Gross profit | $1.95B | $524M | +273% |
| Operating income | $500M | $18M | +2666% |
| Net income | $370M | −$18M | to a profit |
| Diluted EPS | $2.71 | −$0.14 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Amvuttra | $809M | 67% |
| Rare | $142M | 12% |
| Royalty | $72M | 6.0% |
| GIVLAARI | $58M | 4.8% |
| Collaborations | $47M | 3.9% |
| Development Services Obligation | $40M | 3.3% |
| OXLUMO | $19M | 1.5% |
| ONPATTRO | $9.9M | 0.8% |
| Other License Programs | $5.8M | 0.5% |
| Product And Service Other | $1.7M | 0.1% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: H1 2026Total $1.20B (+7.7%)
Development Services Obligation grew +141% year on yearResearch Services Obligation -106% year on year
Segment Latestquarter on quarteryear on year
- Amvuttra$809.1M$809.1Mquarter on quarter +15%year on year +124%+15%+124%
- Rare$141.9M$141.9Mquarter on quarter +13%year on year +11%+13%+11%
- Royalty$71.7M$71.7Mquarter on quarter +46%year on year +79%+46%+79%
- GIVLAARI$58.0M$58.0Mquarter on quarter +18%year on year +5.2%+18%+5.2%
- Collaborations$47.2M$47.2Mquarter on quarter -43%year on year -23%-43%-23%
- Development Services Obligation$40.2M$40.2Mquarter on quarter +17%year on year +141%+17%+141%
- OXLUMO$18.5M$18.5Mquarter on quarter +9.3%year on year +16%+9.3%+16%
- ONPATTRO$9.9M$9.9Mquarter on quarter -3.0%year on year -55%-3.0%-55%
- Other License Programs$5.8M$5.8Mquarter on quarter -85%year on year -70%-85%-70%
- Product And Service Other$1.7M$1.7Mquarter on quarter +34%year on year +4.9%+34%+4.9%
- C5 License Obligation$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- Regeneron Technology Transfer Obligation$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- Research Services Obligation−$802.0K−$802.0Kquarter on quarter -112%year on year -106%-112%-106%
On our screens:R&D leaders